Journal of Medicinal Chemistry · 2020 · 60 citations · 26 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyComplement DisordersComplement SystemComplement System PharmacologyComplement-targeted TherapyEnzyme InhibitionGlomerular Disease PharmacotherapyAtypical Hemolytic Uremic Syndrome TherapyC3 ConvertaseC5 ConvertaseCocrystal FormationComplement Inhibitor DevelopmentFactor B InhibitionParoxysmal Nocturnal Hemoglobinuria TherapySmall-molecule Complement Inhibitors
The alternative pathway (AP) of the complement system is a key contributor to the pathogenesis of several human diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and various glomerular diseases. The serine protease factor B (FB) is a key node in the AP and is integral to the formation of C3 and C5 convertase. Despite the prominent role of FB in the AP, selective orally bioavailable inhibitors, beyond our own efforts, have not been reported previously. Herein we describe in more detail our efforts to identify FB inhibitors by high-throughput screening (HTS) and leveraging insights from several X-ray cocrystal structures during optimization efforts. This work culminated in the discovery of LNP023 (41), which is currently being evaluated clinically in several diverse AP mediated indications.
26
Robyn Reynolds, M. Elizabeth Hartnett, John P. Atkinson et al. · Investigative Ophthalmology & Visual Science · 2009 · 289 citations · Full text
Structures of C3b in Complex with Factors B and D Give Insight into Complement Convertase Formation
Federico Forneris, Daniel Ricklin, Jin Wu et al. · Science · 2010 · 277 citations